Another RCT examining 35 adolescents with suboptimally controlled T1D (HbA1c 7.5–11%) and features of insulin resistance (insulin requirements >0.9 IU/kg/d) showed no improvement in glycemic control when pioglitazone was administered for six months and compared to a placebo. This evidence concerns the gene INS and type 1 diabetes mellitus.